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Abstract
Background: Cerebral small vessel disease (CSVD) is a common cause of stroke, dementia, and functional decline.
In recent years, neuroradiologic correlates of CSVD have been identified. These imaging findings, best characterized
on magnetic resonance imaging (MRI), include some combination of white matter hyperintensities, lacunes,
cerebral microbleeds, enlarged perivascular spaces, and cerebral atrophy. Though some cohorts have reported that
participants with type 2 diabetes mellitus (T2DM), an important risk factor for CSVD, may have a distinct
neuroradiologic phenotype, this relationship is not well-characterized. Adults with diabetes mellitus have a two- to
threefold higher incidence of ischemic stroke compared to controls and are an increasingly important population
given global trends of increasing diabetes prevalence. This study aims to determine if adults with CSVD and T2DM
have a distinct neuroradiologic phenotype.
Methods: A systematic search of the literature will be conducted to find articles that report the MRI features of
CSVD in a cohort of participants including those with and without type 2 diabetes mellitus (T2DM). A number of
databases will be searched including MEDLINE, Embase, CINAHL, and Web of Science. Proceedings and abstracts
from key conferences will also be reviewed and relevant journals hand searched for additional papers. The
references from selected papers will be scanned. Screening of potential articles, data extraction, and quality
appraisal will be performed in duplicate by independent reviewers. Odds ratios and 95% confidence intervals for
the presence versus absence of each neuroradiologic correlate of interest from each included study will be
calculated. If sufficient homogeneity exists among studies, a meta-analysis will be performed for each
neuroradiologic correlate of CSVD. If heterogeneity of studies precludes data pooling, results will be presented in
narrative form.
Discussion: Determining whether a distinct neuroradiologic phenotype of CSVD exists in adults with T2DM will
provide insight into the underlying mechanisms of CSVD and guide future research on therapeutic targets.
Systematic review registration: PROSPERO CRD42016046669
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Background
Cerebral small vessel disease (CSVD) is a neurodegener-
ative condition affecting the small blood vessels of the
brain. In contrast to cerebral large vessels, small vessels
are not visualized by contemporary imaging methods
and therefore cerebral small vessel disease is used to de-
scribe the parenchyma lesions rather than the underlying
small vessel alterations [1]. The neuroimaging correlates
of CSVD include lacunar infarcts, white matter hyperin-
tensities, enlarged perivascular spaces, microbleeds, and
brain atrophy [2]. CSVD is a neuroradiological diagnosis
and the above findings may occur in adults with or with-
out a history of clinically manifest stroke or dementia
[3]. However, the presence and severity of CSVD neuro-
imaging correlates are associated with risk factor burden,
baseline cognition and function, and prognosis with re-
spect to recurrent stroke and cognitive decline [4–6].
CSVD is estimated to affect 250,000 people in Canada
alone and this number is anticipated to rise as the popu-
lation ages. CSVD contributes to 20% of ischemic stroke
[3, 4] and 45% of dementias and the current estimated
direct (medical expenses) and indirect (lost productivity)
costs of stroke and dementia in Canada exceeds $30 bil-
lion annually [6, 7]. There are few known effective ther-
apies for CSVD. Treatment remains empiric and is
directed at controlling vascular risk factors including
hypertension, dyslipidemia, smoking, and hyperglycemia.
Unlike large artery disease, these conventional risk fac-
tors may explain only a small proportion of CSVD,
highlighting the need for targeted therapies.
It is not known whether there is a sequential progres-
sion of neuroradiological findings of CSVD, where the
appearance of certain imaging features consistently pre-
cedes others [7]. Further, certain neuroimaging features
of CSVD seem to co-aggregate more consistently than
others [5, 8]. Insights regarding risk factors for these
separate “phenotypes” of CSVD may yield novel insights
with respect to the mechanism of this disease and direct
therapeutic strategies in the future.
People with diabetes are an important population
given the increasing global burden of the disease (esti-
mated at over 400 million) and the substantially elevated
incidence of stroke (two- to threefold higher) in people
with diabetes compared to controls without diabetes [9].
In the recent Secondary Prevention of Small Subcortical
Strokes (SPS3) trial, which included participants with re-
cent lacunar infarcts, those with a history of diabetes
had distinct neuroimaging characteristics on magnetic
resonance imaging (MRI) as compared with those with-
out diabetes, with an increased odds of posterior circula-
tion infarcts and a lower burden of microbleeds and
enlarged perivascular spaces [10–12]. Whether this
phenotype is consistently observed in other cohorts is
not known.
The most recent systematic review examining brain
imaging findings in adults with diabetes excludes dis-
cussion of findings such as microbleeds and enlarged
perivascular spaces that have only more recently been
widely described in larger contemporary cohorts in
the medical literature [13]. Furthermore, this review
combined findings from both MRI and computed
tomography (CT) studies, which introduces substan-
tial heterogeneity as CT has reduced sensitivity for
detecting findings of CSVD, in particular mild-to-
moderate white matter hyperintensities, cerebral
microbleeds, or enlarged perivascular spaces. Given
that a distinct neuroimaging phenotype of CSVD may
underlie distinct pathophysiological mechanisms and
therapeutic strategies in adults with T2DM, we will
perform an updated systematic review of the literature
to compare MRI neuroimaging features of CSVD in
adults with versus T2DM.
Aim
To determine whether a unique neuroradiologic pheno-
type of CSVD is found in adults with T2DM. This will
be achieved by comparing the presence and severity ver-
sus absence of features of cerebral small vessel disease
(white matter hyperintensities, lacunar infarcts, cerebral
microbleeds, and/or enlarged perivascular spaces) on
MRI in adults with T2DM versus adults without T2DM.
This protocol conforms to the PRISMA-P guidelines
[14] [see Additional file 1].
Inclusion and exclusion criteria
Our research question does not strictly align with the
traditional “Patient, Intervention, Comparison, Out-
come” (PICO) format. For clarity, we will separately de-
scribe the inclusion and exclusion criteria for study
participants, MRI scans, exposure (diabetes mellitus, as
described below), and outcomes separately.
Participants
Participants
Studies of interest are those which include adults aged
18 or older receiving brain MRI for any reason. Studies
must include a group of patients with and without dia-
betes mellitus. Patients in either group with other risk
factors for CSVD (i.e., hypertension, dyslipidemia,
cigarette smoking) shall not be excluded.
MRI
The MRI scanner type and the sequences obtained must
be stated in the paper or data supplement. If such infor-
mation is not described, we will attempt to contact the
authors to obtain this information. If the information
cannot be obtained, the study would be excluded. The
sequences obtained must be deemed by the reviewers to
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be acceptable for determination of the imaging features
reported in the study (see Table 1).
Acceptable MRI modalities for assessing CSVD fea-
tures include T1 and T2/T2 fluid-attenuated inversion
recovery (FLAIR) imaging for white matter hyperintensi-
ties, lacunes, and enlarged perivascular spaces and either
T2*-gradient echo or susceptibility-weighted imaging
(SWI) for cerebral microbleeds [1].
Exposure
The exposure being considered is presence of diabetes.
The method used to identify patients with diabetes must
be stated in the paper. To maximize sensitivity, multiple
definitions of diabetes status will be accepted; those
based on fasting blood glucose, oral glucose tolerance
test, hemoglobin A1c, use of anti-diabetes medications,
or physician/hospital records will be deemed acceptable.
Studies which do not include a description of how pa-
tients with diabetes were identified will be excluded.
Specification of the duration of diabetes or a measure of
disease severity (hemoglobin A1c, presence of end-organ
damage, or history of ketoacidosis or hyperosmolar state
[15]) will not be required for inclusion, though this in-
formation will be extracted if available and will contrib-
ute towards assessment of risk of bias. If specifically
identified, participants with type 1 diabetes shall be ex-
cluded and if diabetes type is not specified in the paper,
the authors will be contacted for clarification.
Outcomes
Primary outcomes include the presence of MRI features
of CSVD (any of: white matter hyperintensities, lacunar
infarcts, cerebral microbleeds and/or enlarged perivascu-
lar spaces). Secondary outcomes focus on the severity of
MRI features of CSVD as per qualitative rating scales.
Studies must include a rating system for presence and/
or severity of the included imaging feature(s) and must
report the prevalence/severity of the feature(s) separately
for subjects with and without diabetes. Studies which do
not report results separately for participants with versus
without diabetes shall be excluded. Commonly used, val-
idated rating systems (examples in Table 1) are pre-
ferred, but novel rating schemes will be deemed
acceptable if they are adequately described as deter-
mined by consensus. Studies which use only a novel rat-
ing scheme that is not adequately described (by
consensus) shall be excluded if attempts to contact the
authors do not yield adequate clarification. If studies
contain data regarding the presence and/or severity of
cerebral atrophy, we will extract these data as well. How-
ever, studies reporting cortical atrophy alone are to be
excluded because this finding in and of itself is not
unique to CSVD.
Types of studies
We will consider any studies that report MRI features of
CSVD (at least one of white matter hyperintensities, la-
cunar infarcts, cerebral microbleeds, enlarged perivascu-
lar spaces) in adults with and without T2DM. To be
eligible for inclusion, a study must report MRI findings
for groups of participants both with and without dia-
betes mellitus. To maximize sensitivity, we will place no
limitations on whether the imaging rater/s is/are blinded
to clinical information, whether there is a measure of
intra-rater/inter-rater reliability, or whether the level of
experience or background (radiologist, neurologist, etc.)
of the raters is specified though this information will be
extracted if available and will contribute towards
Table 1 Description of neuroimaging features of cerebral small vessel disease on MRI
International consensus definition [2] Common rating scales/
definitions
Examples of features




Signal abnormality of variable size in the white matter with
hyperintensity on T2-weighted images without cavitation







• ARWMC score of 5 or
greater (moderate–severe)
• Fazekas periventricular = 3
and/or deep ≥2
• WMH volume ≥7.7 mL [3]
Lacunar infarcts Round/ovoid subcortical fluid-filled cavity 3–15 mm in diameter in the





Small (≤10 mm) areas of signal void with associated blooming on










Fluid-filled spaces following the typical course of a vessel through
grey or white matter, isointense to CSF on all sequences. Linear when
images parallel to the vessel and round or ovoid when perpendicular.
In constrast with lacunes, no T2-hyperintense rim on T2/FLAIR unless
they traverse WMH
• Edinburgh score
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assessment of risk of bias. Studies will be observational;
cohort, case control, and cross-sectional study designs
will be eligible for inclusion. The anticipation is that the
vast majority of these studies will be cross-sectional. We
will only include studies reporting the presence versus
absence of at least one of these four MRI changes in the
total number of participants with versus without dia-
betes (2 × 2 table). These data are sufficient to calculate
odds ratios [16].
Methods
Adherence to preferred reporting standards for system-
atic review is confirmed with the PRISMA-P checklist
(Additional file 1).
The study is registered with PROSPERO (CRD42016046669).
Search method for identification of studies
Scoping searches were undertaken to ensure it was ap-
propriate to commence a systematic review. A concise
MEDLINE (Ovid) search resulting in 147 references
which were reviewed by TS and CF. Records from the
17 papers they selected and five known papers were ex-
amined in MEDLINE (Ovid). The MeSH terms were
reviewed and categorized which contributed to the
conceptualization of the search and the construction of
the draft search.
The intention of the review is to retrieve studies that
include a population of adults with and without diabetes
who have had a brain MRI examining the presence of
CSVD. The most sensitive search would include the
search concepts CSVD and MRI, but this results in an
unmanageable number of results. Therefore, these two
concepts will be combined with diabetes mellitus which
should capture the majority of relevant papers. The
above strategy may miss articles in which the study
population is not described in the abstract of some
papers or not all populations may be mentioned, there-
fore these papers, which could be missed using the will
be captured through two other searches. Search two will
include CSVD, MRI, and adverse effects. Search three
will include CSVD but only studies where this is the
main focus of the paper which will be combined with
MRI. The three searches will be combined using the
Boolean operator OR and duplicates will be removed.
Together, the three searches should create a sensitive
search strategy to capture relevant studies for this review
(see Fig. 1). The subject headings of studies meeting the
inclusion criteria will be examined to ensure all relevant
terms have been captured. If needed, additional searches
will be undertaken.
The initial search will be developed in MEDLINE and
adapted for the following databases: Embase (Ovid),
CINAHL (EBSCOhost) and Web of Science (Thomson
Reuters). Results will be restricted to after 1985 as litera-
ture before 1985 would be prior to the clinical use of MRI.
A language restriction shall not be applied to the search. If
there are relevant non-English abstracts, attempts shall be
made to translate them wherever possible. An illustration
describing the search conceptualization and a draft search
are included as Fig. 1 and Additional file 2.
In regard to grey literature, the proceedings of the
International Stroke Conference, European Stroke
Conference, European Stroke Organization, World
Stroke Organization, the American Diabetes Associ-
ation Scientific Sessions, the World Diabetes Con-
gress, and the Annual General Meeting of the
American Society of Neuroradiology will be searched.
General searches through PapersFirst (WorldCat),
ProceedingsFirst (WorldCat), and Web of Science
(Thomson Reuters) will also be undertaken. The web-
sites of pertinent organizations will also be examined
for papers and the names of researchers.
Fig. 1 Schematic of search concepts
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Several approaches will be undertaken to increase our
retrieval of relevant articles. The journals Stroke, Inter-
national Journal of Stroke, Journal of Stroke and Cere-
brovascular Diseases, Lancet Neurology, Diabetes,
Neuroradiology, and American Journal of Neuroradiol-
ogy will be hand-searched to ensure studies have not
been missed. These journals are considered to be of the
highest impact for the clinical subject of interest. Subject
experts on CSVD will also be contacted to enquire about
any studies felt to be applicable but not retrieved by our
search strategy. Papers meeting the inclusion criteria will
be searched in the Web of Science (Thomson Reuters)
and Elsevier ScienceDirect for articles citing these pa-
pers. References from included papers will also be
reviewed.
Data collection
A record will be kept of all searches and search decisions
to ensure reproducibility. Search results will be exported
to a citation management program (EndNote ver. 7.0).
Duplicates will be removed and retained separately. The
resulting references will be exported separately to the
two reviewers for independent review using MS Excel.
Selection of studies
Two authors (CF, TF) will independently screen all titles
and abstracts identified through the literature searches
and will exclude all records clearly not meeting inclusion
criteria. Disagreements will be resolved by consensus.
The selection process will be pilot tested to ensure a
high degree of agreement between reviewers. Full text of
the remaining studies will then be retrieved. The same
two authors (CF, TF) will independently assess the pa-
pers for fulfillment of inclusion criteria. In case of differ-
ences of opinion regarding study inclusion, a third
review author (SY) will serve as arbiter. To avoid double
counting, if multiple publications based on the same co-
hort of participants are retrieved, only the study report-
ing the largest sample size will be used. The reasons for
excluding papers for which the full text was retrieved
will be documented.
Data extraction and management
A data extraction form will be used to collect details
from the included studies. The form includes informa-
tion on study design, patient population, and presence of
neuroimaging features of interest (see Additional file 3).
Two review authors (CF and TF) will independently ex-
tract the data. The data extraction form will be pilot
tested on several papers to ensure consistency and that
all relevant information is being captured. If necessary, a
statistician will review the extraction of data to further
ensure quality and reliability. Authors will be contacted
for missing data.
We will extract the MRI features of interest (white
matter hyperintensities, lacunar infarcts, cerebral micro-
bleeds, and/or enlarged perivascular spaces, cerebral at-
rophy) accounted for in the study as well as any rating
scales used. “Presence” versus “absence” of each feature
will be determined as per Table 1. For studies using an
alternate rating scale not included in Table 1, criteria for
“presence” versus “absence” will be discussed between
the raters (CF, TF) and with an additional expert if
deemed necessary. For each feature included, we will ex-
tract 2 × 2 tables (presence versus absence of MRI find-
ings in subjects with versus without diabetes) from
publications, or we will reconstruct these from data in
the publication. For studies where the data does not per-
mit a 2 × 2 table construction, we will contact the study
authors to ask for the relevant data before deciding
whether or not to exclude the study from the systematic
review. Presence of adjustment for relevant covariates
(i.e., smoking status, age, hypertension, dyslipidemia)
and the covariates themselves included in the analysis
will be recorded.
Assessment of methodological quality
We will assess the methodological quality of each study
using the Quality Assessment Tool for Observational
Cohort and Cross-sectional Studies from the National
Heart, Lung and Blood Institute [17]. This tool was de-
signed to provide a framework to focus on the key con-
cepts for establishing the internal validity of cohort and
cross-sectional studies. Use of a more rigorous assess-
ment tool is precluded by the primarily cross-sectional
nature of our data.
Two authors (CF, TF) will assess methodological
quality independently and will resolve all disagree-
ments through discussion or with arbitration by a
third author (SY).
Data synthesis and statistical analysis
We anticipate that there may be significant heterogen-
eity in the prevalence of MRI features of CSVD in sub-
jects with versus without diabetes across studies. There
are several factors that could contribute to such hetero-
geneity. These factors include the following: differences
in demographic and clinical features (e.g., age, hyperten-
sion, renal disease, smoking, duration and severity of
diabetes) among study cohorts; differences in definitions
of diabetes; technical differences between MRI scanners
and acquisition protocols (e.g., magnet strength, slice
thickness, sequences); use of different radiological rating
scales; and differences in MRI rater skill and reliability.
An I2 statistic will be calculated for the studies to be in-
cluded in each proposed meta-analysis (i.e. for each neu-
roradiologic correlate of interest) with values of 25, 50,
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and 75% suggesting low, moderate, or high degrees of
heterogeneity, respectively [18].
Scales which report a dichotomized (i.e., present or
absent) or categorical (i.e., absent, mild, moderate, se-
vere) shall be harmonized for meta-analysis if deemed
appropriate by our statistician. Other types of rating
scales shall not be included in a meta-analysis and
the data based on any such data scale would be pre-
sented in narrative form.
If significant heterogeneity between studies, as de-
termined by consultation with our statistician, pre-
vents meaningful pooling of the data, we will limit
ourselves to providing a narrative description of ob-
served trends. This would include a summary of the
design of each of the studies reporting the preva-
lence of each CSVD feature and the odds ratio for
presence of that feature from each individual study.
If some studies (at least two) may be pooled into a
meta-analysis, then for each CSVD feature we will
calculate odds ratios and 95% confidence intervals for
the presence of the features in subjects with versus
without diabetes from the 2 × 2 tables extracted from
the data collection forms. Given the heterogeneity of
the populations studied, assumption of a fixed effect
size across populations would not be justified, thus
analyses would be performed using a random effects
model [19]. Given the dichotomized (presence or ab-
sence) or categorical (severity measure) nature of our
data of, meta-analysis will be performed using the
Mantel-Haenzel method [20].
If there are sufficient data to allow such analyses
(in principle from as few as a single high quality
study, but if possible by pooling data from multiple
studies), we will perform subgroup analyses for par-
ticipants with renal disease and participants with
hypertension. In addition, if sufficient data are avail-
able, we shall perform subgroup analyses by age and
diabetes duration.
For diagnostic studies, knowledge of the mechanisms
that may induce publication bias or empirical absence for
its existence is sparse (in contrast to intervention studies),
however, we will attempt to assess for publication bias
using Deeks’ test [21]. Funding sources and conflict of
interest will be extracted from included studies.
Statistical analysis will be performed using RevMan
software [22].
Quality of evidence
A summary of findings table will be created. We will
use the Grading of Recommendations, Assessment,
Development and Evaluation (GRADE) approach to
assess the quality of evidence for the primary out-
comes of interest [23].
Discussion
The neuroradiologic correlates of CSVD have only been
fully described in the last decade. Much research still re-
mains into how the risk factors for CSVD lead to the
emergence of the particular pathologic and neuroradio-
logic correlates. Patients with diabetes mellitus represent
a large portion of adults with CSVD. Although any ef-
fects of elevated glucose may be “dose-dependent” (i.e.,
dependent on severity and duration of diabetes), we
hypothesize that even dichotomized categorization of
participants into those with versus without diabetes will
reveal significant differences between these two groups,
when adjusted for confounding risk factors such as age
or history of hypertension.
Whether or not such a distinct phenotype is uncov-
ered by this review, additional analyses examining other
CSVD risk factors (i.e., hypertension) and their relation-
ship to a distinct phenotype would further clarify pos-
sible mechanisms of CSVD and help to guide targeted
therapeutic strategies.
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